688331 荣昌生物
已收盘 01-21 15:00:01
资讯
新帖
简况
荣昌生物（688331）披露限制性股票激励计划归属结果，1月21日股价下跌0.07%
证券之星 · 01-21 22:17
荣昌生物（688331）披露限制性股票激励计划归属结果，1月21日股价下跌0.07%
荣昌生物：首次回购19.4144万股
南方财经网 · 01-20 18:53
荣昌生物：首次回购19.4144万股
【券商聚焦】中泰国际上调荣昌生物(09995)评级至“买入” 指泰它西普与维迪西妥单抗的2025年销售收入将快速增加
金吾财讯 · 01-19 13:47
【券商聚焦】中泰国际上调荣昌生物(09995)评级至“买入” 指泰它西普与维迪西妥单抗的2025年销售收入将快速增加
每周股票复盘：荣昌生物（688331）与艾伯维签署49.5亿美元授权协议
证券之星 · 01-18
每周股票复盘：荣昌生物（688331）与艾伯维签署49.5亿美元授权协议
荣昌生物：公司尚无药品在欧盟获批上市，无药品向欧盟出口销售
每日经济新闻 · 01-16
荣昌生物：公司尚无药品在欧盟获批上市，无药品向欧盟出口销售
荣昌生物(09995)升3.45% 与艾伯维就RC148达成独家授权许可
金吾财讯 · 01-16
荣昌生物(09995)升3.45% 与艾伯维就RC148达成独家授权许可
智通港股早知道 | 央行下调各类结构性货币工具25个基点 国家电网“十五五”计划投资4万亿元
智通财经 · 01-16
智通港股早知道 | 央行下调各类结构性货币工具25个基点 国家电网“十五五”计划投资4万亿元
荣昌生物：调整回购股份价格上限至116元/股
每日经济新闻 · 01-15
荣昌生物：调整回购股份价格上限至116元/股
华西证券：维持荣昌生物(09995)“增持”评级 RC148双抗56亿美元出海
智通财经 · 01-15
华西证券：维持荣昌生物(09995)“增持”评级 RC148双抗56亿美元出海
【券商聚焦】交银国际维持荣昌生物(09995)买入评级 看好泰它西普和维迪西妥在海外注册研究上的进展
金吾财讯 · 01-14
【券商聚焦】交银国际维持荣昌生物(09995)买入评级 看好泰它西普和维迪西妥在海外注册研究上的进展
智通港股通活跃成交|1月13日
智通财经 · 01-13
智通港股通活跃成交|1月13日
国产双抗再爆发：荣昌生物达成首付款6.5亿美元BD，盘中一度涨停
澎湃新闻 · 01-13
国产双抗再爆发：荣昌生物达成首付款6.5亿美元BD，盘中一度涨停
荣昌生物拿下56亿美元大单，双抗技术缘何频获跨国巨头追捧？
21世纪经济报道 · 01-13
荣昌生物拿下56亿美元大单，双抗技术缘何频获跨国巨头追捧？
异动快报：荣昌生物（688331）1月13日11点25分触及涨停板
证券之星 · 01-13
异动快报：荣昌生物（688331）1月13日11点25分触及涨停板
商业航天大面积跌停，AI应用继续大涨
大河财立方 · 01-13
商业航天大面积跌停，AI应用继续大涨
PD-1/VEGF双抗交易热潮回归？荣昌生物签下56亿美元授权
第一财经 · 01-13
PD-1/VEGF双抗交易热潮回归？荣昌生物签下56亿美元授权
荣昌生物与艾伯维达成肿瘤治疗药物合作 股价料高开15%
美股速递 · 01-13
荣昌生物与艾伯维达成肿瘤治疗药物合作 股价料高开15%
智通港股早知道 | 四部门印发《关于加强政府投资基金布局规划和投向指导的工作办法(试行)》 隔夜中概股指数涨4.26%
智通财经 · 01-13
智通港股早知道 | 四部门印发《关于加强政府投资基金布局规划和投向指导的工作办法(试行)》 隔夜中概股指数涨4.26%
荣昌生物与艾伯维达成独家许可协议 最高可获50亿美元里程碑付款
美股速递 · 01-12
荣昌生物与艾伯维达成独家许可协议 最高可获50亿美元里程碑付款
荣昌生物(09995)与艾伯维就RC148签署独家授权许可协议
智通财经 · 01-12
荣昌生物(09995)与艾伯维就RC148签署独家授权许可协议
加载更多
公司概况
公司名称：
荣昌生物制药(烟台)股份有限公司
所属行业：
医药制造业
上市日期：
2022-03-31
主营业务：
荣昌生物制药(烟台)股份有限公司的主营业务是抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物的研发、生产和销售。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC88、RC148、RC278、RC288。泰它西普发明专利先后获得中国、美国、欧洲等国家和地区的授权，得到了国家“十一五”、“十二五”、“十三五”期间“重大新药创制”科技重大专项支持。
发行价格：
48.00
{"stockData":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":103.53,"timestamp":1768978801000,"preClose":103.6,"halted":0,"volume":5804400,"delay":0,"changeRate":-0.0007,"floatShares":162000000,"shares":564000000,"eps":-1.6788,"marketStatus":"已收盘","change":-0.07,"latestTime":"01-21 15:00:01","open":103.83,"high":106.8,"low":102.4,"amount":606000000,"amplitude":0.0425,"askPrice":103.53,"askSize":22,"bidPrice":103.48,"bidSize":5,"shortable":0,"etf":0,"ttmEps":-1.6788,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1769045400000},"marketStatusCode":5,"adr":0,"adjPreClose":103.6,"symbolType":"stock_kcb","openAndCloseTimeList":[[1768959000000,1768966200000],[1768971600000,1768978800000]],"highLimit":113.96,"lowLimit":93.24,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":564477483,"isCdr":false,"pbRate":25.15,"roa":"--","roe":"--","epsLYR":-2.73,"committee":0.015385,"marketValue":58361000000,"turnoverRate":0.0358,"status":1,"afterMarket":{"amount":0,"volume":0,"close":103.53,"buyVolume":0,"sellVolume":0,"time":1768980837558,"indexStatus":"已收盘 01-21 15:30:00","preClose":103.6},"hkstockBrief":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":93.8,"timestamp":1768982936009,"preClose":94,"halted":0,"volume":4559720,"delay":0,"premium":"-19.14"},"floatMarketCap":16806000000},"requestUrl":"/m/hq/s/688331","defaultTab":"news","newsList":[{"id":"2605488754","title":"荣昌生物（688331）披露限制性股票激励计划归属结果，1月21日股价下跌0.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605488754","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605488754?lang=zh_cn&edition=full","pubTime":"2026-01-21 22:17","pubTimestamp":1769005037,"startTime":"0","endTime":"0","summary":"截至2026年1月21日收盘，荣昌生物报收于103.53元，较前一交易日下跌0.07%，最新总市值为584.4亿元。公司近日发布公告称，荣昌生物制药（烟台）股份有限公司已完成2022年及2023年A股限制性股票激励计划相关权益的归属，共计归属767,240股，涉及激励对象142人。本次归属新增股份已于2026年1月20日完成登记，上市流通日期为2026年1月26日。股本总数由563,710,243股增至564,477,483股，实际控制人未发生变更。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100040789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","LU2148510915.USD","BK0239","09995","BK1161","LU2328871848.SGD","BK1574","LU2488822045.USD","LU1064131003.USD","BK1583","LU1969619763.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2604923661","title":"荣昌生物：首次回购19.4144万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2604923661","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604923661?lang=zh_cn&edition=full","pubTime":"2026-01-20 18:53","pubTimestamp":1768906388,"startTime":"0","endTime":"0","summary":"南财智讯1月20日电，荣昌生物公告，公司于2026年1月20日通过上海证券交易所交易系统以集中竞价交易方式首次回购股份194,144股，占公司总股本的0.0344%，回购价格区间为102.17元/股至103.78元/股，支付资金总额为2000.40万元（不含交易费用）。本次回购方案已实施完成，实际回购金额为2000.40万元，在预计回购金额2000万元至4000万元范围内。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601203624836419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064131003.USD","BK0239","BK1583","LU1969619763.USD","LU2148510915.USD","BK1161","LU1064130708.USD","LU2328871848.SGD","09995","BK1574","LU2488822045.USD","688331"],"gpt_icon":0},{"id":"2604864900","title":"【券商聚焦】中泰国际上调荣昌生物(09995)评级至“买入” 指泰它西普与维迪西妥单抗的2025年销售收入将快速增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2604864900","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604864900?lang=zh_cn&edition=full","pubTime":"2026-01-19 13:47","pubTimestamp":1768801676,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰国际研报指，荣昌生物 日前与全球行业巨头艾伯维签订关于肿瘤领域的双抗药物RC148的授权协议，公司将授予艾伯维RC148在大中华区以外地区的的开发、生产和商业化的独家权利，协议获准后公司将获6.5亿美元的首付款及最高49.5亿美元的开发、监管和商业化里程碑付款，以及在大中华以外地区净销售额的两位数分级特许权使用费。艾伯维的认可表明产品临床数据优异，而且首付款将显著夯实资金。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973487","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","688331"],"gpt_icon":0},{"id":"2604928774","title":"每周股票复盘：荣昌生物（688331）与艾伯维签署49.5亿美元授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2604928774","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604928774?lang=zh_cn&edition=full","pubTime":"2026-01-18 01:59","pubTimestamp":1768672747,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，荣昌生物报收于107.25元，较上周的96.96元上涨10.61%。本周，荣昌生物1月13日盘中最高价报114.46元。本周关注点交易信息汇总：荣昌生物因涨幅达15%登上龙虎榜。公司公告汇总：荣昌生物与艾伯维签署RC148全球授权协议，获6.5亿美元首付款及最高49.5亿美元里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1583","LU1064131003.USD","09995","LU1969619763.USD","LU2488822045.USD","LU2148510915.USD","LU1064130708.USD","LU2328871848.SGD","688331","BK1161","BK0239"],"gpt_icon":0},{"id":"2603967864","title":"荣昌生物：公司尚无药品在欧盟获批上市，无药品向欧盟出口销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2603967864","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603967864?lang=zh_cn&edition=full","pubTime":"2026-01-16 18:25","pubTimestamp":1768559151,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：请问近两年是否出口欧盟国家？荣昌生物（688331.SH）1月16日在投资者互动平台表示，公司尚无药品在欧盟获批上市，无药品向欧盟出口销售，未来业务的开展情况，还请您关注公司的相关公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601163622035255.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601163622035255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","LU1969619763.USD","LU2328871848.SGD","BK1583","LU2488822045.USD","LU1064130708.USD","LU2148510915.USD","688331","LU1064131003.USD","BK0239","09995","BK1574"],"gpt_icon":0},{"id":"2603954004","title":"荣昌生物(09995)升3.45% 与艾伯维就RC148达成独家授权许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2603954004","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603954004?lang=zh_cn&edition=full","pubTime":"2026-01-16 13:35","pubTimestamp":1768541754,"startTime":"0","endTime":"0","summary":"金吾财讯 | 荣昌生物(09995)股价午后维持高位，截至发稿，升3.45%，报97.65港元，成交额3.21亿港元。交银国际研究报告指，荣昌生物与艾伯维就RC148达成独家授权许可协议，后者将获得RC148大中华区以外开发、生产和商业化的独家权利，荣昌生物将收到6.5亿美元首付，并最高49.5亿美元的里程碑收款，以及两位数百分比的分级销售提成。该行上调荣昌生物2026至27年的收入预测，升目标价至136港元。2026年看好泰它西普和维迪西妥在海外注册研究上的进展，以及早期品种在更多适应症上的进展。","market":"other","thumbnail":"https://static.szfiu.com/news/20241105/OGZjY2Y5NjEzNTIxNjU5NDU5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241105/OGZjY2Y5NjEzNTIxNjU5NDU5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973389","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688331","BK0239","LU1064130708.USD","09995","BK1161","LU1064131003.USD","BK1583","LU2148510915.USD","LU2328871848.SGD","LU1969619763.USD","LU2488822045.USD","BK1574"],"gpt_icon":0},{"id":"2603349619","title":"智通港股早知道 | 央行下调各类结构性货币工具25个基点 国家电网“十五五”计划投资4万亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603349619","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603349619?lang=zh_cn&edition=full","pubTime":"2026-01-16 07:52","pubTimestamp":1768521142,"startTime":"0","endTime":"0","summary":"修订后的eCTD相关技术文件由国家药监局药品审评中心另行发布。国家电网“十五五”计划投资4万亿元据中国电力报消息，国家电网“十五五”投资计划出炉：“十五五”期间，国家电网公司固定资产投资预计达到4万亿元，较“十四五”投资增长40%;将重点聚焦于绿色转型、构建新型电力系统、强化科技赋能等方面。持有屈臣氏集团25%股份的淡马锡寻求在其IPO中退出投资。双方所持股份均设有5年锁定期。2025年公司获得钠电千吨级订单并出货。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"66a50ec980ff2cb7251ac80144af961f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393600.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0032431581.USD","06936","CKHUY","ZTmain","LU0320764599.SGD","BK4588","LU1048588211.SGD","00001","LU1571399168.USD","BK1230","BK1569","BK4505","BK4532","09866","BK1110","02190","ZNmain","LU0052750758.USD","02579","LU0149721374.USD","BK1601","LU0708995583.HKD","BK1161","ZFmain","LU0072462343.USD","ZBmain","BK1100","02465","BK4534","LU0164880469.USD","BK4574","603993","BK4509","LU1481107354.HKD","03993","BK1587","BK4504","LU1969619763.USD","BK1574","BK4548","EVS.SI","UBmain","NIO.SI","300919","BK1116","002352","TNmain","BK1500","BK1151","BK1592","BK4526","BK4585","BK1594","BK1521","BK4531","LU2328871848.SGD","688331","BK4581","603906","BK1583","LU1880383440.USD","LU1880383366.USD","LU2213484517.USD","BK4555","NIO","BK4099","BK1190","09995"],"gpt_icon":1},{"id":"2603670626","title":"荣昌生物：调整回购股份价格上限至116元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2603670626","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603670626?lang=zh_cn&edition=full","pubTime":"2026-01-15 16:55","pubTimestamp":1768467316,"startTime":"0","endTime":"0","summary":"【荣昌生物：调整回购股份价格上限至116元/股】1月15日，荣昌生物公告称，公司拟将回购价格上限由95元/股调整为116元/股，以保障回购股份方案顺利实施。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601153620451798.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601153620451798.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064131003.USD","LU2488822045.USD","BK1574","BK1583","LU2148510915.USD","09995","BK1161","688331","LU1064130708.USD","BK0239","LU1969619763.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2603027626","title":"华西证券：维持荣昌生物(09995)“增持”评级 RC148双抗56亿美元出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2603027626","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603027626?lang=zh_cn&edition=full","pubTime":"2026-01-15 09:11","pubTimestamp":1768439514,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华西证券发布研报称，维持荣昌生物“增持”评级，公司自主研发实力强劲，核心产品销售稳定增长，管理团队经验丰富，临床适应症管线稳定推进，海内外布局合理，看好公产品上市后商业化运营能力。根据协议，艾伯维将获得RC148在大中华区以外地区的独家开发、生产和商业化权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393091.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09995","688331","002926"],"gpt_icon":0},{"id":"2603540866","title":"【券商聚焦】交银国际维持荣昌生物(09995)买入评级 看好泰它西普和维迪西妥在海外注册研究上的进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2603540866","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603540866?lang=zh_cn&edition=full","pubTime":"2026-01-14 09:04","pubTimestamp":1768352684,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，荣昌生物 宣布与艾伯维就RC148达成独家授权许可协议，后者将获得RC148大中华区以外开发、生产和商业化的独家权利，公司将收到6.5亿美元首付款、最高49.5亿美元的里程碑收款、以及两位数百分比的分级销售提成。随着关键产品相继BD出海，2026年该机构看好泰它西普和维迪西妥在海外注册研究上的进展，以及早期品种在更多适应症上的推进，相关数据读出有望持续催化股价。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250106/YTg5NTFiOTlmZmEyYmE3ODE4NjgwNzc4MTUzMTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/YTg5NTFiOTlmZmEyYmE3ODE4NjgwNzc4MTUzMTI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973172","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688331","09995"],"gpt_icon":0},{"id":"2603168844","title":"智通港股通活跃成交|1月13日","url":"https://stock-news.laohu8.com/highlight/detail?id=2603168844","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603168844?lang=zh_cn&edition=full","pubTime":"2026-01-13 19:00","pubTimestamp":1768302001,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2026年1月13日当天，阿里巴巴-W、腾讯控股、小米集团-W位居沪港通（南向）成交额前3位，成交额分别为81.05 亿元、29.45 亿元、28.57 亿元；阿里巴巴-W、腾讯控股、小米集团-W 位居深港通（南向）成交额前3位，成交额分别为58.01 亿元、23.48 亿元、21.05 亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1044875133.USD","LU0738912210.USD","LU1568876335.HKD","LU1831875114.USD","BK1531","LU1951186391.HKD","LU1642822792.SGD","LU0541501648.USD","SG9999014674.SGD","80883","LU0173614495.USD","LU1880383440.USD","LU0117841782.USD","LU0661504455.SGD","SGXZ51526630.SGD","LU0231483743.USD","LU0979878070.USD","HTCD.SI","LU0572940350.SGD","LU1152091754.HKD","BK1607","LU0633140560.USD","SG9999015986.USD","LU2488822045.USD","IE00B0169N27.USD","LU0672654166.SGD","BK4614","LU2265009873.SGD","SG9999001226.SGD","IE0008368304.USD","LU0143863198.USD","09995","SG9999002562.SGD","LU2106854487.HKD","LU0210533765.USD","81024","LU1282651048.USD","IE00B5MMRT66.SGD","LU1048588211.SGD","LU0197773673.USD","SGXZ81514606.USD","LU0499858438.USD","BK4527","LU2177674079.SGD","01810","HK0000352382.USD","BK4587","BK1523","BK4543","LU2778985437.USD","LU0348814723.USD","LU0107464264.USD","LU1235295612.USD","LU0326950275.SGD","LU1439103000.SGD","LU0370786039.SGD","03690","LU2399975544.HKD","SG9999014898.SGD","BK1501","LU0289960550.SGD","LU0543330483.HKD","LU1328277881.USD","LU1770036033.HKD","LU0868486357.SGD","LU1733274390.USD","BK1238","LU1880398554.USD","LU0320764599.SGD","LU2097828474.EUR","IE00BZ08YR35.GBP","BK4220","LU0456842615.SGD","LU0164880469.USD","LU1883866441.USD","LU0545039389.USD","LU2097828805.USD","LU2237443895.HKD","SGXZ31699556.SGD","IE0003795394.USD","LU0831093199.SGD","LU0862451837.USD","SG9999001689.USD","LU0449509016.USD","LU0873338254.USD","BK1546","LU0608807433.USD","LU0384037296.USD","LU0918141887.USD","LU0831103253.SGD","LU2237443382.USD","LU0211331839.USD","LU0509642566.USD","LU0469268626.HKD","LU0577902454.USD","IE00B8L5B284.USD","LU0456846285.SGD","LU0708995153.HKD","LU0630378692.HKD","LU0572944931.SGD","LU2097828631.EUR","LU0117844026.USD","LU0348784397.USD","LU0244354667.USD","LU0828237940.HKD","LU1720051017.SGD","IE00B3M56506.USD","BK1536","LU2476274720.SGD","LU1282651121.HKD","LU0096374516.USD","LU2125910500.SGD","LU0192582467.USD","LU0143863784.USD","688981","LU0320764243.SGD","LU0577902371.SGD","BK1618","LU0594300179.USD","LU1242518857.USD","LU1064130708.USD","LU1282649141.HKD","LU2125910849.SGD","LU0165289439.USD","LU0543330566.HKD","LU0823397285.USD","09988","LU0737861699.HKD","LU2476274308.USD","LU0130103400.USD","LU0203345920.USD","LU1769817096.USD","IE0008368742.USD","LU1810669033.SGD","LU2097828714.EUR","LU0072913022.USD","LU0310800965.SGD","LU0345776255.USD","LU2008162690.USD","LU2449936058.SGD","BK1528","IE00BQXX3C00.GBP","LU0011963245.USD","LU0797268264.HKD","LU3063872942.SGD","LU1115378108.SGD","SG9999000327.SGD","LU0516422952.EUR","BK4535","LU1242518931.SGD","SG9999003461.SGD","LU1720051108.HKD","LU0329678170.USD","BK1574","LU0708995583.HKD","LU1196710195.USD","BK1141","002202","BK1584","HK0000306701.USD","LU1211504680.USD","LU0516423091.SGD","LU0588545730.USD","LU1814569148.SGD","LU0821914370.USD","LU1497734951.SGD","89988","LU0235996351.USD","LU0784639295.USD","LU0871576103.HKD","LU1282649810.SGD","BK1609","LU2357305700.SGD","LU2279701549.SGD","LU0737861772.HKD","LU1548497426.USD","LU0823413660.USD","IE00B543WZ88.USD","BK1506","LU0791590937.USD","BK1588","IE00B031HW06.USD","LU1316542783.SGD","LU0634319403.HKD","SG9999007991.SGD","LU0048580855.USD","LU0314109678.HKD","LU1044876610.USD","SG9999015952.SGD","SG9999018865.SGD","LU0878004406.USD","LU0865486749.SGD","00981","LU1993786604.SGD","LU0348788117.USD","LU2045819591.USD","LU0463099449.HKD","02228","HK0000500386.USD","IE00B031J352.USD","LU1196710351.USD","LU0293314216.USD","SG9999004220.SGD","LU1328615791.USD","LU0106252389.USD","LU0588546209.SGD","LU0328353924.USD","LU0251144936.SGD","LU1961090484.USD","IE0008369823.USD","IE00B031HY20.USD","LU1634259391.SGD","LU1804176565.USD","LU0345769128.USD","LU0577902611.USD","LU0786609619.USD","LU0127658192.USD","LU0039217434.USD","IE0008368411.USD","IE00BZ08YT58.USD","LU0210527791.USD","LU0210526637.USD","02208","HK0000914686.HKD","LU0823413587.USD","LU0441854154.USD","LU0132412106.USD","LU0163747925.USD","LU1823568750.SGD","LU0128522744.USD","LU1366334578.USD","LU0203347892.USD","LU0149721374.USD","LU0211977185.USD","LU0642271901.SGD","IE00BF5LJ272.USD","LU1152091168.USD","BK4581","LU2251237306.USD","BK1249","LU0823426480.USD","LU2247934214.USD","LU0890818403.SGD","LU0577902538.SGD","LU1323998911.USD","LU0414403682.SGD","BK1591","LU1497733631.SGD","LU1102505929.USD","BK1152","LU2023250504.SGD","LU0531971595.HKD","LU1785774172.SGD","IE00BZ08YS42.EUR","LU0175139822.USD","LU0261950983.USD","LU0502904849.HKD","LU2242644610.SGD","LU2362541273.HKD","LU0048597586.USD","LU0359201612.USD","LU2226246903.HKD","HK0000914660.USD","LU0359202008.SGD","LU1048596156.SGD","BK1526","HXXD.SI","LU0049112450.USD","SG9999001069.SGD","SG9999001903.USD","LU0084288322.USD","LU0348767384.USD","LU2097828557.USD","IE0031814852.USD","BK4558","LU1226288097.SGD","BK1615","BK1095","LU1981816686.USD","LU1808992512.USD","LU0264606111.USD","GB00BDT5M118.USD","LU1770034418.SGD","SG9999002828.SGD","LU0762542818.HKD","BK4534","IE0009570106.USD","LU0287142896.SGD","LU0633140727.USD","BK1233","LU0431992006.USD","LU0128522157.USD","BK4503","IE00BFMHRM44.USD","LU1515016050.SGD","BK1617","IE00BPRC5H50.USD","LU0348825331.USD","LU1868837565.USD","LU0878005551.USD","HK0000252152.HKD","00700","LU0327786744.USD","LU1046422090.SGD","LU0149534421.HKD","LU1226287529.USD","LU0315179316.USD","LU1720050803.USD","IE0003851619.USD","LU1003077747.HKD","LU0067412154.USD","600938","LU1226287875.USD","LU0648948544.HKD","BK4575","SG9999001846.SGD","IE00B067MR52.USD","LU0348735423.USD","LU1497733557.USD","IE00BGV7N243.SGD","IE0032834883.USD","LU0605514214.HKD","LU0348766576.USD","LU2257852520.SGD","IE00B0JY6N72.USD","LU0348783662.USD","LU0918141705.HKD","LU0828237510.HKD","LU1960683339.HKD","LU0882747503.HKD","SG9999006514.SGD","LU0516423174.USD","LU0307460666.USD","LU0029874905.USD","HK0000165453.HKD","LU0329678337.USD","LU2362541513.USD","LU0531970944.HKD","LU1794554557.SGD","BK1558","HK0000252160.HKD","BK4607","LU0417516571.SGD","LU0072462343.USD","SG9999000459.SGD","LU1917777945.USD","IE00BMPRXR70.SGD","LU1969619763.USD","SG9999006597.SGD","IE00B97KM107.HKD","LU0588545490.SGD","LU0700851271.USD","LU0169518387.USD","BK4548","LU1188198961.HKD","LU0588545904.SGD","LU0593848301.USD","LU0315178854.USD","LU1048484197.HKD","IE00BMPRXN33.USD","SG9999002463.SGD","BK4531","IE0034224299.USD","LU0856984785.SGD","SG9999018857.SGD","LU0540923850.HKD","BK1502","LU0043850808.USD","LU0516422440.USD","LU1226287792.SGD","BK1516","02269","LU0359201885.HKD","LU0553294199.USD","LU0577902298.EUR","LU0828238088.HKD","LU1044874839.SGD","BK4554","LU1734074674.USD","LU1868837722.USD","BK1142","LU0417516902.SGD","LU0052750758.USD","LU0762541174.USD","LU0345775950.USD","LU2293587155.HKD","BK1610","LU2039709279.SGD","BK1575","BK4538","LU0348783233.USD","81810","IE00B0169L03.USD","LU0886674414.USD","LU2251237488.HKD","BK1576","LU1046421795.USD","SG9999001051.SGD","BK1586","LU0348816934.USD","LU0823426308.USD","LU0985320562.USD","BK1517","LU1725190679.HKD","LU0572939691.SGD","BK1583","BK4579","LU1105468828.SGD","BK1521","BK1513","LU0823038988.USD","LU0648000940.SGD","IE00BQXX3F31.USD","LU2328871848.SGD","LU0791591158.USD","SG9999014906.USD","LU0501845795.SGD","00883","BK1163","LU0214875030.USD","LU2237443549.SGD","LU2148510915.USD","LU1675838814.USD","LU0061477393.USD","BK1614","LU0477156797.USD","LU0823039010.USD","IE0032431581.USD","BK1589","LU1023057109.AUD","SG9999013353.USD","688331","BK4585","LU0181495838.USD","HK0000320264.USD","09926","LU1196710864.SGD","BK4526","LU0049853897.USD","LU1251922891.USD","SG9999017495.SGD","LU0054450605.USD","LU0047713382.USD","LU0326948709.USD","BK4502","LU1688375341.USD","LU0228659784.USD","LU2133065610.SGD","SG9999015945.SGD","LU0164872284.USD","LU1568876251.USD","LU0499858602.USD","LU1956131251.USD","LU1807302812.USD","IE0003895053.USD","LU0029875118.USD","BK1594","LU0269904917.USD","LU0320764755.SGD","SGXZ49509284.SGD","LU0251143458.SGD","BK4565","LU1282648689.USD","LU0650527681.SGD","BK4505","LU1051769294.HKD","IE00B29SXG58.USD","LU0456827905.SGD","LU1201861165.SGD","LU0972618739.USD","LU0229945570.USD","LU2097829019.USD","LU1366334651.USD","LU1481107354.HKD","IE0001KFT4U8.USD","LU1439102457.SGD","BK4533","LU1868838027.USD","LU0417516738.SGD","LU0130518102.USD","KSTmain","LU2317271919.USD","LU1719994722.HKD","LU0675040207.SGD","BK4524","LU0738911758.USD","LU1267930227.SGD","HK0000306685.HKD","LU0541502299.USD","BK4504","LU0949170772.SGD","LU0051755006.USD","00941","LU0164865239.USD","SG9999015978.USD","LU0762540952.USD","LU1655091459.SGD","HBBD.SI","METmain","LU1880398471.USD","LU0188438112.USD","LU0880133367.SGD","LU2498475776.HKD","LU0054237671.USD","BK1205","LU0070217475.USD","BK0214","LU0396098781.USD","LU0196878994.USD","LU0640798160.USD","LU0819123356.HKD","BK1590","LU0862451753.SGD","HK0000320223.HKD","LU0589944569.HKD","LU1226288253.USD","LU0630378429.USD","600941","LU0345769631.USD","LU1522347837.USD","IE00B8HQ1Z84.USD","LU0608807946.USD","SGXZ99366536.SGD","LU1102505762.USD","LU1634259557.SGD","LU0254981946.USD","LU0228367735.SGD","LU1974910355.USD","BK1604","LU0140636845.USD","BABA","SGXZ90724238.SGD","LU0048388663.USD","LU0516422366.SGD","LU0128525689.USD","LU0106959298.USD","LU0348827113.USD","LU2362540622.SGD","HMTD.SI","LU2051468812.USD","LU0611395673.USD","LU1008478684.HKD","LU0348805143.USD","SG9999014880.SGD","SGXZ81163826.USD","LU0080751232.USD","01024","LU0823397103.USD","LU0607220059.USD","LU1235294995.USD","LU2237443465.HKD","LU0898667661.SGD","LU0449515922.USD","LU0488056044.USD","LU1051768304.USD","SG9999000418.SGD","LU1224709979.USD","LU2152927971.USD","LU0348723411.USD","LU1226288170.HKD","LU1880383366.USD","LU1504937902.USD","HK0000352291.HKD","LU2148611432.USD","LU2087589342.USD","LU2237443978.SGD","LU1064131003.USD","LU0197773160.USD","LU0259732245.USD","BK1608","LU0594300419.USD","LU0651947912.USD","BK4588","BK4122","LU0561508036.HKD","BK1161","LU1224444064.USD","LU0823040885.USD","LU0052756011.USD","LU2462611646.USD","LU1303224171.USD","BK1193","LU0106259558.USD","LU0819121731.USD","LU1813983027.USD","LU2237443622.USD","SG9999001093.SGD","LU1733274473.HKD","LU1718418525.SGD","LU1282649067.USD","LU1769817179.HKD","LU0455707207.USD","LU0261947096.USD","LU0651946864.USD","LU0823041008.USD","LU1629966141.USD","SG9999014914.USD","LU0683595622.HKD","IE00BQXX3D17.EUR"],"gpt_icon":0},{"id":"2603577631","title":"国产双抗再爆发：荣昌生物达成首付款6.5亿美元BD，盘中一度涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2603577631","media":"澎湃新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603577631?lang=zh_cn&edition=full","pubTime":"2026-01-13 13:25","pubTimestamp":1768281912,"startTime":"0","endTime":"0","summary":"1月13日，荣昌生物（688331.SH；9995.HK）A股高开，截至午盘，A股20cm涨停，港股涨超11%。消息面上，1月12日晚间，荣昌生物公告称，与知名跨国药企艾伯维（AbbVie）就荣昌生物自主研发的新型靶向PD-1/VEGF的双特异性抗体药物RC148签署独家授权许可协议。根据协议，艾伯维将获得RC148在大中华区以外地区的独家开发、生产和商业化权利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601133617176389.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601133617176389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064130708.USD","LU2488822045.USD","BK1161","LU2328871848.SGD","09995","LU1969619763.USD","BK0239","BK1574","LU1064131003.USD","BK1583","688331","LU2148510915.USD"],"gpt_icon":0},{"id":"2603957431","title":"荣昌生物拿下56亿美元大单，双抗技术缘何频获跨国巨头追捧？","url":"https://stock-news.laohu8.com/highlight/detail?id=2603957431","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603957431?lang=zh_cn&edition=full","pubTime":"2026-01-13 12:11","pubTimestamp":1768277460,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛肿瘤双抗治疗的战场再次传来重磅消息，一家中国创新药企与跨国巨头的牵手，不仅是单个药物的授权，更是全球肿瘤治疗格局加速演变的信号。1月12日，艾伯维（纽约证 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20260113/c673966897.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20260113/c673966897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["LU1064130708.USD","LU2148510915.USD","688331","LU2488822045.USD","LU1064131003.USD","BK0239"],"gpt_icon":0},{"id":"2603275579","title":"异动快报：荣昌生物（688331）1月13日11点25分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2603275579","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603275579?lang=zh_cn&edition=full","pubTime":"2026-01-13 11:30","pubTimestamp":1768275040,"startTime":"0","endTime":"0","summary":"证券之星1月13日盘中消息，11点25分荣昌生物触及涨停板。其所属行业生物制品目前上涨。领涨股为近岸蛋白。该股为创新药，健康中国，医药概念热股，当日创新药概念上涨2.7%，健康中国概念上涨2.51%，医药概念上涨2.3%。1月12日的资金流向数据方面，主力资金净流出826.53万元，占总成交额1.25%，游资资金净流入2303.75万元，占总成交额3.49%，散户资金净流出1477.22万元，占总成交额2.24%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300015725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK1574","LU1969619763.USD","LU2328871848.SGD","BK1161","LU2148510915.USD","LU2488822045.USD","09995","688331","LU1064130708.USD","BK1583","BK0239"],"gpt_icon":0},{"id":"2603575987","title":"商业航天大面积跌停，AI应用继续大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2603575987","media":"大河财立方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603575987?lang=zh_cn&edition=full","pubTime":"2026-01-13 10:06","pubTimestamp":1768270010,"startTime":"0","endTime":"0","summary":"大河财立方记者 夏晨翔 任浩鹏1月13日开盘，A股三大指数集体高开后震荡，医疗、CRO、生物科技、AI应用、文化传媒、虚拟人、AIGC、保险等概念涨幅居前；商业航天、卫星导航、低空经济、卫星互联网等概念跌幅居前。12日晚间，多个热门赛道概念股发布异常波动、风险提示、停牌核查公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011310120797a189a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011310120797a189a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1868838027.USD","LU0819123356.HKD","SG9999006597.SGD","LU0052750758.USD","LU1328277881.USD","300063","000547","LU0348805143.USD","BK1522","LU1188198961.HKD","002149","LU0516422440.USD","LU0359201612.USD","SG9999015945.SGD","002413","LU0572944931.SGD","LU0164872284.USD","603259","LU0823038988.USD","LU1023057109.AUD","LU2476274720.SGD","LU0417516738.SGD","LU0417516902.SGD","BK1594","LU0871576103.HKD","002044","IE00BD6J9T35.USD","LU0516422952.EUR","LU0469268626.HKD","LU0865486749.SGD","LU0314109678.HKD","301230","03986","81211","LU2294711713.HKD","LU0979878070.USD","LU1808992512.USD","LU0605514214.HKD","LU2476274308.USD","LU0588546209.SGD","LU0588545730.USD","300785","BK1582","LU2039709279.SGD","LU1794554557.SGD","LU0449515922.USD","LU0359201885.HKD","LU0634319403.HKD","LU0348827113.USD","603598","LU1242518931.SGD","LU2506951792.HKD","LU0594300419.USD","LU0708995583.HKD","LU1719994722.HKD","LU1868837722.USD","LU0244354667.USD","LU2348774022.SGD","LU0449509016.USD","LU1961090484.USD","LU2357125470.USD","LU0259732245.USD","LU0511384066.AUD","LU1813983027.USD","HYDD.SI","LU0359202008.SGD","300244","LU1251922891.USD","LU0320764599.SGD","LU1880383366.USD","LU0588545490.SGD","BK1540","LU0175139822.USD","LU0307460666.USD","LU0054450605.USD","09988","LU0165289439.USD","LU0588545904.SGD","LU0540923850.HKD","LU0594300179.USD","LU0516423174.USD","SG9999015986.USD","01211","688331","LU2097828805.USD","SG9999002828.SGD","LU0516423091.SGD","LU0211977185.USD","LU0348735423.USD","LU0823414478.USD","LU0348825331.USD","LU0823426308.USD","SG9999002463.SGD","LU2097828631.EUR","600151","LU1861214812.USD","600986","LU0509642566.USD","LU2097828714.EUR","09995","LU0531971595.HKD","BYDDY","LU2360107325.USD","LU0828238088.HKD","LU0505663152.USD","002594","LU0823414551.USD","LU0289739343.SGD","LU1861219969.SGD","LU0823426480.USD","LU2449936058.SGD","SG9999001226.SGD","LU1242518857.USD","LU0593848301.USD","LU1868837565.USD","LU0289961442.SGD","BK1539","LU0143863198.USD","SG9999006514.SGD","LU0143863784.USD","LU0254981946.USD","LU1303224171.USD","LU0039217434.USD","LU0315178854.USD","00241","LU2153592121.USD","LU2249611893.SGD","SG9999014674.SGD","LU1770034418.SGD","02359","LU0531970944.HKD","SG9999015952.SGD","SG9999015978.USD","BK1119","LU2097828557.USD","LU0561508036.HKD","LU0543330566.HKD","LU0823039010.USD","LU0084288322.USD","09868","LU0856984785.SGD","LU2778985437.USD","LU0164865239.USD","LU0043850808.USD","LU0214875030.USD","LU0269904917.USD","LU0289960550.SGD","LU0327786744.USD","LU0819121731.USD","LU1720050803.USD","301171","LU2097828474.EUR","BK1610","LU0516422366.SGD","BK1509","LU0326950275.SGD","LU0650527681.SGD","LU1880383440.USD","601698","603986","LU0463099449.HKD","LU2399975544.HKD","LU0229945570.USD","002131","600880"],"gpt_icon":1},{"id":"2603357301","title":"PD-1/VEGF双抗交易热潮回归？荣昌生物签下56亿美元授权","url":"https://stock-news.laohu8.com/highlight/detail?id=2603357301","media":"第一财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603357301?lang=zh_cn&edition=full","pubTime":"2026-01-13 10:03","pubTimestamp":1768269780,"startTime":"0","endTime":"0","summary":"艾伯维拿下荣昌生物的双抗授权。 1月12日晚间，中国生物医药企业荣昌生物宣布，与艾伯维达成一笔总金额高达56亿美元的授权合作。 RC148是荣昌生物研发的一款新型靶向PD-1/VEGF的双特异性抗体药物，其设计旨在激活抗肿瘤免疫反应的同时抑制肿瘤驱动的血管生成。通过同时靶向并抑制PD-1与VEGF通路，有望通过多机制增强免疫系统的抗肿瘤活性。 值得一提的是，康方生物PD-1/VEGF再度传来新的进展消息。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-01-13/doc-inhhcntx9294031.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-01-13/doc-inhhcntx9294031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PD","BK1574","BK4023","LU1064130708.USD","LU2148510915.USD","LU2328871848.SGD","688331","LU2488822045.USD","LU1169590202.USD","LU1969619763.USD","BK1583","BK0239","BK1161","LU1064131003.USD","LU1169589451.USD","09995"],"gpt_icon":0},{"id":"1177111409","title":"荣昌生物与艾伯维达成肿瘤治疗药物合作 股价料高开15%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177111409","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177111409?lang=zh_cn&edition=full","pubTime":"2026-01-13 09:29","pubTimestamp":1768267758,"startTime":"0","endTime":"0","summary":"中国生物制药企业荣昌生物宣布与跨国药企艾伯维就实验性肿瘤治疗药物达成战略合作。受此消息提振，市场预期该公司股价开盘将上涨15%。\n此次合作聚焦于创新肿瘤疗法的研发与商业化，标志着荣昌生物在全球化战略布局中迈出关键一步。双方将整合研发资源，加速推进实验性抗肿瘤药物的临床进展。\n分析人士指出，与国际制药巨头艾伯维的合作不仅能为荣昌生物带来资金支持，更有助于提升其创新药物的国际认可度。该合作预计将显著增强投资者对公司在肿瘤治疗领域技术实力的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064130708.USD","BK0239","LU1064131003.USD","LU2488822045.USD","LU2148510915.USD","688331"],"gpt_icon":0},{"id":"2603229535","title":"智通港股早知道 | 四部门印发《关于加强政府投资基金布局规划和投向指导的工作办法(试行)》 隔夜中概股指数涨4.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603229535","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603229535?lang=zh_cn&edition=full","pubTime":"2026-01-13 07:43","pubTimestamp":1768261383,"startTime":"0","endTime":"0","summary":"四部门联合印发《关于加强政府投资基金布局规划和投向指导的工作办法(试行)》国家发展改革委等四部门联合印发《关于加强政府投资基金布局规划和投向指导的工作办法(试行)》。热门中概股多数收涨，纳斯达克中国金龙指数涨4.26%，阿里巴巴涨超10%，创8月29日以来最大涨幅；哔哩哔哩涨近9%，小鹏汽车涨超8%。减持后最新持股数目约为47.19亿股，最新持股比例为70.20%。指纹识别模组销售数量合计1794.7万件，环比增加0.9%，同比减少12%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1634259557.SGD","BK1119","BK1614","BK1163","688331","LU0264606111.USD","LU1497733557.USD","BK1610","LU1634259391.SGD","BK1607","LU1497733631.SGD","BK1526","LU0572940350.SGD","LU0456827905.SGD","09995","BK1231","LU1497734951.SGD","LU1522347837.USD","BK1560","LU0051755006.USD","LU0572939691.SGD","BK1161","BK1117","LU0210526637.USD"],"gpt_icon":1},{"id":"1172926155","title":"荣昌生物与艾伯维达成独家许可协议 最高可获50亿美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1172926155","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172926155?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:59","pubTimestamp":1768222756,"startTime":"0","endTime":"0","summary":"荣昌生物宣布与跨国药企艾伯维签署独家许可协议。根据协议条款，荣昌生物有资格获得累计最高达50亿美元的里程碑付款。此次合作涉及特定创新药物的全球商业化权益，标志着中国生物科技企业在国际授权交易领域取得重大突破。协议具体覆盖的治疗领域及阶段性付款细节尚未披露，但业内人士指出，这笔交易规模创下中国生物科技企业对外授权的新纪录。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","LU2148510915.USD","BK0239","LU1064130708.USD","688331","LU1064131003.USD"],"gpt_icon":0},{"id":"2602517177","title":"荣昌生物(09995)与艾伯维就RC148签署独家授权许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2602517177","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602517177?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:54","pubTimestamp":1768222464,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物(09995)发布公告，于2026年1月12日，公司与艾伯维集团控股公司(艾伯维)就RC148签署独家授权许可协议。RC148是公司研发的一款新型靶向PD-1/VEGF的双特异性抗体药物。根据协议，艾伯维将获得RC148在大中华区以外地区的的开发、生产和商业化的独家权利。协议经相关监管批准生效后，公司将收到6.5亿美元的首付款，并有资格获得最高达49.5亿美元的开发、监管和商业化里程碑付款，以及在大中华区以外地区净销售额的两位数分级特许权使用费。协议中所约定的里程碑付款需要满足一定的条件，公司最终可实现的里程碑付款金额尚存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391856.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2148510915.USD","BK1574","BK1583","LU1969619763.USD","LU2488822045.USD","688331","LU1064131003.USD","LU2328871848.SGD","BK1161","09995","LU1064130708.USD","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1769039048601,"stockEarnings":[{"period":"1week","weight":0.0018},{"period":"1month","weight":0.2956},{"period":"3month","weight":0.1873},{"period":"6month","weight":0.5526},{"period":"1year","weight":2.7241},{"period":"ytd","weight":0.3309}],"compareEarnings":[{"period":"1week","weight":-0.0022},{"period":"1month","weight":0.0509},{"period":"3month","weight":0.0496},{"period":"6month","weight":0.1456},{"period":"1year","weight":0.2696},{"period":"ytd","weight":0.0373}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"荣昌生物制药(烟台)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15248人(较上一季度增加18.39%)","perCapita":"10696股","listingDate":"2022-03-31","address":"山东省烟台市福山区中国(山东)自由贸易试验区烟台片区烟台开发区北京中路58号","registeredCapital":"56447万元","survey":" 荣昌生物制药(烟台)股份有限公司的主营业务是抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物的研发、生产和销售。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC88、RC148、RC278、RC288。泰它西普发明专利先后获得中国、美国、欧洲等国家和地区的授权，得到了国家“十一五”、“十二五”、“十三五”期间“重大新药创制”科技重大专项支持。","listedPrice":48},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,688331,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}